PR Newswire BiotechnologyCodex · 实盘不做把握 2/10
北京时间·🕒 发布 23:14:00时区推断·⟳ 抓取 23:15:50·⚡ 决策 07-27 23:16:18 +28s·91.7 天前
云顶新耀宣布参加即将举行的投资者会议
本次仅公告管理层参加 Morgan Stanley 和 Evercore 投资者会议,未披露临床、监管、商业化、财务或交易层面的新增事实。
📄 原文PR Newswire Biotechnology↗ 原文
Everest Medicines Announces Participation in Upcoming Investor Conferences
SHANGHAI, July 27, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceuti…
不做 云顶新耀(01952.HK)
常规投资者会议参会公告,无明确方向、无可量化新增基本面影响,不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-27 · 扩散 low · price-in 风险 medium ↗
关键理由
- 本次仅公告管理层参加 Morgan Stanley 和 Evercore 投资者会议,未披露临床、监管、商业化、财务或交易层面的新增事实。
主要风险
- 会议期间若另行披露管线、销售或授权进展,应由新信号重新研判。
原文全文
展开原文 · 3,192 字
Everest Medicines Announces Participation in Upcoming Investor Conferences
SHANGHAI, July 27, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Ian Woo, President and Chief Financial Officer, will participate in the upcoming investor conferences.
Morgan Stanley Biotech Without Borders Series
Date: Tuesday, July 28, 2026
Time: US: 10:00am – 10:30am ET / 10:00pm – 10:30pm HKT
Format: Fireside chat
Webcast: https://morganstanley.webcasts.com/starthere.jsp?ei=1771095&tp_key=ca5039df5f
2nd Annual Evercore China Biotech Summit
Date: Tuesday, August 18, 2026
Time: 11:00am HKT
Format: Presentation and Q&A
Location: The Ritz-Carlton Shanghai, Pudong
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. The Company's therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com.
Forward-Looking Statements
This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects", "anticipates", "future", "intends", "plans", "believes", "estimates", "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
SOURCE Everest Medicines
SHANGHAI, July 27, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Ian Woo, President and Chief Financial Officer, will participate in the upcoming investor conferences.
Morgan Stanley Biotech Without Borders Series
Date: Tuesday, July 28, 2026
Time: US: 10:00am – 10:30am ET / 10:00pm – 10:30pm HKT
Format: Fireside chat
Webcast: https://morganstanley.webcasts.com/starthere.jsp?ei=1771095&tp_key=ca5039df5f
2nd Annual Evercore China Biotech Summit
Date: Tuesday, August 18, 2026
Time: 11:00am HKT
Format: Presentation and Q&A
Location: The Ritz-Carlton Shanghai, Pudong
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. The Company's therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com.
Forward-Looking Statements
This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects", "anticipates", "future", "intends", "plans", "believes", "estimates", "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
SOURCE Everest Medicines
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。